The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

 The global glioblastoma multiforme (GBM) treatment market is on an upward trajectory, with expectations to grow from $2.04 billion in 2022 to $2.26 billion in 2023, showcasing a robust compound annual growth rate (CAGR) of 10.3%. As we explore the factors contributing to this growth, it becomes apparent that the increasing prevalence of brain disorders, coupled with technological advancements, is shaping the landscape of GBM treatment.

Prevalence of Brain Disorders: Catalyst for Growth

• Understanding Brain Disorders: Abnormal functioning of the brain and nerves, including conditions like glioblastoma multiforme (GBM), is driving the demand for effective treatments.
• Contributing Factors: The rise in brain disorders is attributed to various factors, including an aging population, compromised immune systems, overdiagnosis, ionizing radiation, and air pollution.
• Global Statistics: Globocan reported 308,102 cases of brain and central nervous system cancers globally in 2020, emphasizing the critical need for treatment. In the U.S., the American Cancer Society estimates 25,050 new cases of brain or spinal cord cancer in 2022.
• Market Implication: The increasing prevalence of brain disorders, with GBM at the forefront, is a primary driver propelling the GBM treatment market towards a projected size of $3.26 billion in 2027 at a CAGR of 9.7%.

Key Players in the GBM Treatment Market

• Industry Leaders: Merck & Co Inc., F. Hoffmann-La Roche AG, Amgen Inc., Pfizer Inc., and other major players are pivotal in shaping the GBM treatment market.
• Diverse Participation: The involvement of companies such as Carl Zeiss AG, Varian Medical Systems, Novartis AG, and others illustrates the diverse landscape of the market.
• Strategic Landscape: The market’s competitiveness prompts ongoing research and development initiatives to innovate and maintain market positions.

Advancements in Therapies: A Transformative Trend

• Focused Innovation: Companies are channeling efforts into research and development to bring about innovative therapies. A notable example is Daiichi Sankyo Company Limited, which launched DELYTACT in November 2021.
• Oncolytic Virus-Based Immunotherapy: DELYTACT represents the first oncolytic virus-based immunotherapy, utilizing Teserpaturev. This innovative approach involves genetically modified viruses that selectively replicate in cancer cells, triggering anti-cancer immunity without harming healthy cells.
• Unique Features: DELYTACT stands out for its ability to stimulate immune responses, initiate anti-cancer immunity, and target tumor cells that have spread to other parts of the brain.

Market Segmentation

• By Treatment: The GBM treatment market is segmented into Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, and Immunotherapy, offering a diverse range of treatment options.
• By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, and other drug classes provide clinicians with varied pharmaceutical tools to combat GBM.
• By Route of Administration: The choice between Oral, Parenteral, and other routes of administration adds flexibility to treatment options.
• By End-Use: Hospitals, Clinics, and Ambulatory Surgical Centers cater to diverse patient needs and healthcare infrastructures.

Regional Dynamics: North America Leads, Asia-Pacific Emerges

• North American Dominance: In 2022, North America claimed the largest share in the GBM treatment market, highlighting the region’s leadership in shaping market trends.
• Growing Asia-Pacific: The forecast period anticipates Asia-Pacific as the fastest-growing region, underscoring the global expansion of the GBM treatment market.

View More On The Glioblastoma Multiforme (GBM) Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

Request A Sample Of The Global Glioblastoma Multiforme (GBM) Treatment Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=8803&type=smp

The Glioblastoma Multiforme (GBM) Treatment Global Market Report 2023  provides a comprehensive overview on the glioblastoma multiforme (GBM) treatment market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Neurology Devices Global Market Report 2023
Neurostimulation Devices Global Market Report 2023
Neuroprosthetics Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model